Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 52-68 , January 2009

Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy

  • Krishna K. Gaddam, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Krishna K. Gaddam, MD, 115 Community Health Services Building, 933 19th Street South, Birmingham, Alabama 35294. Tel: 205-934-9281; fax: 205-934-1302
    • ,
  • Suzanne Oparil, MD

Received 3 December 2007 ,Accepted 28 June 2008.

References 

  1. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–394
  2. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of heart failure epidemic. JAMA. 2003;289:194–202
  3. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2001;37:1042–1048
  4. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002;105:1928–1933
  5. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol. 1997;30:8–18
  6. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788–1794
  7. Aeschbacher BC, Hutter D, Fuhrer J, Weidmann P, Delacrétaz E, Allemann Y. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens. 2001;14:106–113
  8. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomized trial. Lancet. 2007;369:2079–2087
  9. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992–2997
  10. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104:128–130
  11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259
  12. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118–2121
  13. Solomon SD, Anavekar N, Skali H, McMurray J, Swedberg K, Yusuf S Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738–3744
  14. Persson H, Lonn E, Edner M, Baruch L, Lang C, Morton J Investigators of the CHARM Echocardiographic Substudy–CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence. J Am Coll Cardiol. 2007;49:687–694
  15. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf F, Rademakers F, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550
  16. Hunt SA, Abraham WT, Chin MH, Feldman A, Francis G, Ganiats T, et al. ACC/AHA guidelines update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–e82
  17. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe, part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  18. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen D, Parkhomenko A, Borbola J SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  19. Brutsaert DL. Diastolic heart failure: perception of the syndrome and scope of the problem. Prog Cardiovasc Dis. 2006;49:153–156
  20. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease?. Eur J Heart Fail. 2007;9:136–143
  21. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269
  22. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo V, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209–2216
  23. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768–777
  24. Cain BS, Meldrum DR, Joo KS, Wang J, Meng X, Cleveland JC, et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol. 1998;32:458–467
  25. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part II: causal mechanisms and treatment. Circulation. 2002;105:1503–1508
  26. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959
  27. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema D, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–2096
  28. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568–575
  29. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774–781
  30. Van Heerebeek L, Borbély A, Nissen HWM, Bronzwaer JGF, van der Velden J, Stienen GJM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966–1973
  31. Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43–51
  32. Chan V, Hoey A, Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol. 2006;148:902–908
  33. Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999;48:1443–1447
  34. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558–565
  35. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regulatory Integrative Comp Physiol. 2007;292:946–954
  36. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656–664
  37. Masson S, Staszesky L, Annoni G, Carlo E, Arosio B, Bai A, et al. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. J Card Fail. 2004;10:433–441
  38. Shiparo BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289–295
  39. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function. http://www.clinicaltrials.gov/ct/show/NCT00094302?order = 1. Accessed: September 24, 2007
  40. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2051–2060
  41. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544–2565
  42. Levine BD, Lane LD, Buckey JC, Friedman DB, Blomqvist CG. Left ventricular pressure-volume and Frank-Starling relations in endurance athletes (Implications for orthostatic tolerance and exercise performance). Circulation. 1991;84:1016–1023
  43. Arbab-Zadeh A, Dijk E, Prasad A, Fu Q, Torres P, Zhang R, et al. Effect of aging and physical activity on left ventricular compliance. Circulation. 2004;110:1799–1805
  44. Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006;47:398–402
  45. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252
  46. ALLHAT officers and coordinators for the ALLHAT collaborative research group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). JAMA. 2002;288:2981–2997
  47. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113:2201–2210
  48. ALLHAT Collaborative Research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975
  49. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, et al. Heart failure with preserved and impaired left ventricular systolic function in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2008;Forthcoming
  50. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562
  51. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214–1218
  52. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507–1513
  53. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46
  54. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  55. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684–690
  56. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Trial. Circulation. 2004;110:1456–1462
  57. Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, et al. Change in left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Am Heart J. 2002;144:1057–1064
  58. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 2002;105:1071–1076
  59. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA Trial. J Hypertens. 2001;19:303–309
  60. Tsioufis C, Chatzis D, Dimitriadis K, Stougianos P, Kakavas A, Vlasseros I, et al. Left ventricular diastolic dysfunction is accompanied by increased aortic stiffness in the early stages of essential hypertension: a TDI approach. J Hypertens. 2005;23:1745–1750
  61. Abhayaratna WP, Barnes ME, O'Rourke MF, Gersh BJ, Seward JB, Miyasaka Y, et al. Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients ≥65 years of age. Am J Cardiol. 2006;98:1387–1392
  62. Eren M, Gorgulu S, Uslu N, Celik S, Dagdeviren B, Tezel T. Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart. 2004;90:37–43
  63. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113:1213–1225
  64. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  65. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17:793–801
  66. ACCOMPLISH investigatorsJamerson KA. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. Chicago, Illinois: American College of Cardiology Scientific Sessions; 2008;March 31,
  67. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–1393
  68. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66:981–986
  69. Warner JG, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999;33:1567–1572
  70. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72:853–864
  71. Nishikawa N, Masuyama T, Yamamoto K, Sakata Y, Mano T, Miwa T, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol. 2001;38:1539–1545
  72. Flather MD, Shibata MC, Coats AJS, van Veldhuisen DJ, Parkomenko A, Borbola J, et al. SENIORS investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  73. Ghio S, Magrini G, Serio A, Klersy C, Fucilli A, Ronaszeki A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006;27:562–568
  74. Nodari S, Metra M, Dei Cas L. β-blocker treatment of patients with diastolic heart failure and arterial hypertension (A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol). Eur J Heart Fail. 2003;5:621–627
  75. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114:397–403
  76. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781
  77. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) Study. Eur Heart J. 2006;27:2338–2345
  78. Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M VALIDD investigators. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006;152:246–252
  79. The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction. http://www.clinicaltrials.gov/ct/show/NCT00523549?order = 1. Accessed: September 24, 2007
  80. Izzo J, Pitt B, Oparil S, Desai A, Verma A. Effects on blood pressure lowering with and aggressive versus standard approach in patients with stage II hypertension and diastolic dysfunction: Baseline and blood pressure results of the EXforge intensive Control of hypertension to Evaluate Efficacy in Diastolic Dysfunction (EXCEED) Trial. May New Orleans, LA: The American Society of Hypertension Inc, 23rd Annual Scientific Meeting and Exposition; 2008;
  81. The J-ELAN Investigators. Effect of Losartan and Amlodipine on left ventricular diastolic function in patients with mild-to moderate hypertension (J-ELAN): rationale and design. Circ J. 2006;70:124–128
  82. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10:149–156
  83. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M I-PRESERVE Investigators. The Irbesartan in heart failure with Preserved systolic function (I-PRESERVE) trial: rationale and design. J Cardiac Fail. 2005;11:576–585
  84. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a prelimnary report. Circulation. 2005;112:357–363
  85. Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, Penno G, et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin: a preliminary echocardiography study. Atherosclerosis. 2008;197:346–354
  86. Arias MA, Sánchez-Gila J. Statins and diastolic heart failure. Int J Cardiol. 2007;115:91–92
  87. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2008;294:H1804–H1814
  88. Zile M, Gaasch W, Little W, Francis G, Tavazzi L, Cleland J, et al. MCC-135 GO1 Investigators A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 Study): rationale and design. J Card Fail. 2004;10:193–199
  89. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191–195
  90. Hirsch JC, Borton AR, Albayya FP, Russell MW, Ohye RG, Metzger JM. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2004;286:H2314–H2321
  91. Molina EJ, Palma J, Gupta D, Torres D, Gaughan JP, Houser S, et al. Improvement in hemodynamic performance, exercise capacity, inflammatory profile, and left ventricular reverse remodeling after intracoronary delivery of mesenchymal stem cells in an experimental model of pressure overload hypertrophy. J Thorac Cardiovasc Surg. 2008;135:292–299
  92. Landesberg A, Konyukhov E, Shofti R, Vaknin Y, Shenhav A, et al. Augmentation of dilated failing left ventricular stroke work by a physiological cardiac assist device. Ann N Y Acad Sci. 2004;1015:379–390

 Dr. Gaddam is a postdoctoral fellow supported by Grant NHLBI T32 HL007457. Dr. Oparil is the recipient of Grants-in-Aid from Abbott Laboratories, Astra Zeneca, Aventis, Biovail, Boehringer Ingelheim, Bristol Myers-Squibb, Forest Laboratories, GlaxoSmithKline, Novartis, Merck & Co, Pfizer, Daiichi-Sankyo Pharma, Sanofi-Aventis, and Schering-Plough. Dr. Oparil is a consultant for Bristol-Myers Squibb, Daiichi-Sankyo, Merck & Co., Novartis, Pfizer, Sanofi Aventis, and The Salt Institute.

PII: S1933-1711(08)00140-X

doi: 10.1016/j.jash.2008.06.004

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 52-68 , January 2009

Article Tools

* Image Usage & Resolution